Features of metabolic syndrome in patients with depressive disorder
Authors:
M. Zeman 1; R. Jirák 2; A. Žák 1; M. Jáchymová 1; M. Vecka 1; E. Tvrzická 1; L. Vávrová 1; J. Kodydková 1; B. Staňková 1
Authors‘ workplace:
Univerzita Karlova v Praze, 1. lékařská fakulta a VFN, IV. interní klinika
1; Univerzita Karlova v Praze, 1. lékařská fakulta a VFN, Psychiatrická klinika, Centrum pro Alzheimerovu chorobu a Katedra psychiatrie IPVZ Praha
2
Published in:
Čas. Lék. čes. 2009; 148: 309-314
Category:
Original Article
Overview
Background.
Depressive disorder is a serious illness with a high incidence, proxime accessit after anxiety disorders among the psychiatric diseases. It is accompanied by an increased risk of development of type 2 diabetes mellitus, cardiovascular disease, and by increased all-cause mortality. Recently published data have suggested that factors connected with the insulin resistance are at the background of this association.
Methods and results.
In this pilot study we have investigated parameters of lipid metabolism and glucose homeostasis in consecutively admitted patients suffering from depressive disorder (DD) (group of 42 people), in 57 patients with the metabolic syndrome (MetS) and in a control group of 49 apparently healthy persons (CON). Depressive patients did not differ from the control group by age or body mass index (BMI) value, but they had statistically significantly higher concentrations of serum insulin, C-peptide, glucose, triglycerides (TG), conjugated dienes in LDL particles (CD-LDL), higher value of microalbuminuria and of insulin resistance (HOMA-IR) index. They simultaneously had significantly lower value of the insulin sensitivity (QUICKI) index. In comparison with the MetS group the depressive patients were characterized by significantly lower both systolic and diastolic blood pressure, BMI , serum TG, apolipoprotein B, uric acid, C-peptide and by higher concentrations of apolipoprotein A-I and HDL-cholesterol. On the contrary, we have not found statistically significant differences between the DD and MetS groups in the concentrations of serum insulin, glucose, HOMA and QUICKI indices, in CD-LDL and MAU.
Conclusions.
In this pilot study, we have found in patients with depressive disorder certain features of metabolic syndrome, especially insulin resistance and oxidative stress.
Key words:
depressive disorder, metabolic syndrome, insulin resistance, oxidative stress.
Sources
1. ESEMeD/MHEDEA2000. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology od Mental Disorders (ESEMeD) Project. Acta Psychiatr Scand 2004; 109 (Suppl1): 21–27.
2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436–1442.
3. Zdravotnická ročenka České republiky 2007. Praha: ÚZIS 2008.
4. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of Depression to Diabetes Types 1 and 2: Epidemiology, Biology, and Treatment. Biol Psychiatry 2003; 54: 317–329.
5. Wulsin LR, Vaillant GE, Wells V-E. A systematic review of the mortality of depression. Psychosom Med 1999; 61: 6–17.
6. Chrousos GP. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int. J Obes 2000; 24: S50–S55.
7. Kinder LS, Carnethon MR, Palaniappan LP, et al. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 2004; 66: 316–322.
8. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415–1428.
9. McCaffery JM, Niaura R, Todaro JF, et al. Depressive symptoms and metabolic risk in adult male twins enrolled in the National Heart, Lung, and Blood Institute Twin Study. Psychosom Med 2003; 65: 490–497.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fourth edition. Washington, D. C.: American Psychiatric Association 1994.
11. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469–480.
12. Ahotupa M, Ruutu M, Mantyla E. Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Clin Biochem 1996; 29: 139–144.
13. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
14. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402–2410.
15. Chiba M, Suzuki S, Hinokio Y, et al. Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder. Metabolism 2000; 49: 1145–1149.
16. Okamura F, Tashiro A, Utumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000; 49: 1255–1260.
17. Rasgon N, Altshuler L, Fairbanks L, et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005; 7: 246–259.
18. den Heijer T, Vermeer S, van Dijk E, et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003; 46: 1604–1610.
19. Sheline YI, Wang PW, Gado MH, et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93: 3908–3913.
20. Rasgon NL, Kenna HA. Insulin resistance in depressive disorders and Alzheimer’s disease: Revisiting the missing link hypothesis. Neurobiol Aging 2005; 26: S103–S107.
21. Convit A, De Leon M.J, Tarshish C, et al. Specific hippocampal volume reductions in individuals at risk for Alzheimer’s disease. Neurobiol Aging 1997; 18: 131–138.
22. Shelton RC. The molecular neurobiology of depression. Psychiatr. Clin North Am 2007; 30: 1–11.
23. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistence, diabetes and cardiovascular disease? The common soil hypothesis revisited. Arterioscler. Tromb VascBiol 2004; 24: 816–823.
24. Watson GS, Cholerton BA, Reger MA, et al. Am J Geriatr Psychiatry 2005; 13: 950–958.
25. McLaughlin T, Allison G, Abbasi F, et al. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004; 53: 495–499.
26. Chadwick W, Wilson G, van de Venter M, et al. Shifts in metabolic parameters surrounding glucose homoeostasis resulting from tricyclic antidepressant therapy: implications of insulin resistance? J Pharm Pharmacol 2007; 59: 95–103.
27. Levkovitz Y, Ben-shushan G, Hershkovitz A, et al. Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases. Mol Cell Neurosci 2007; 36: 305–312.
28. Weber-Hamann B, Gilles M, Lederbogen F, et al. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 2006; 67: 1856–1861.
29. Laimer M, Kramer-Reinstadler K, Rauchentauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 2006; 67: 421–424.
30. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006; 5: 157–168.
31. Baldwin DS, Reines EH, Guiton C, Weiller E. Escitalopram Therapy for Major Depression and Anxiety Disorders. Ann Pharmacother 2007; 41: 1583–1589.
32. Žák A, Tvrzická E, Vecka M, et al. Insulin resistance, lipoperoxidation, and fatty acid composition: relationship to metabolic syndrome components in men. Tohoku J Exp Med 2007; 212: 359–371.
33. Tsuboi H, Shimoi K, Kinae N. et al. Depressive symptoms are independently correlated with lipid peroxidation in a female population: comparison with vitamins and carotenoids. J Psychosom Res 2004; 56: 53–58.
34. Khanzode SD, Dakhale GN, Khanzode SS, et al. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re uptake inhibitors. Redox Rep 2003; 8: 365–370.
35. Juurlink BH, Paterson PG. Review of oxidative stress in brain and spinal cord injury: suggestions for pharmacological and nutritional management strategies. J Spinal Cord Med 1998; 2: 309–334.
36. Wu A, Ying Z, Gomez-Pinilla, F. The interplay between oxidative stress and brain-derived neurotrophic factor modulates the outcome of a saturated fat diet on synaptic plasticity and cognition. Eur J Neuroscience 2004; 19: 1699–1707.
37. Stehouwer CD, Smulders, YM. Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol 2006; 17: 2106–2111.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Bilateral spontaneous pneumothorax – wrong therapies
- Human genome sequencing – next generation technology or will the routine sequencing of human genome be possible?
- Eosinophils in the gastrointestinal tract
- On human ageing and longevity – 2. internal determinants